At a glance
| Abbreviation | HuBHV5, HCMV |
|---|---|
| ICTV species | Cytomegalovirus humanbeta5 |
| Family | Orthoherpesviridae |
| Baltimore class | I — dsDNA |
| Human infection | Human infection recorded; pattern not classified |
Also called: human betaherpesvirus 5; human cytomegalovirus; Cytomegalovirus humanbeta5
Duplodnaviria › Peploviricota › Herviviricetes › Herpesvirales › Orthoherpesviridae › Cytomegalovirus
What it is
Taxonomy copied from ICTV MSL41.v1 / VMR_MSL41.v1.20260729.xlsx. These ranks are not hand-edited; a correction means re-running the fetch against a newer release.
| Realm | Duplodnaviria |
|---|---|
| Kingdom | Heunggongvirae |
| Phylum | Peploviricota |
| Class | Herviviricetes |
| Order | Herpesvirales |
| Family | Orthoherpesviridae |
| Subfamily | Betaherpesvirinae |
| Genus | Cytomegalovirus |
| ICTV identifier | ICTV19790333 |
| NCBI taxon | 3050295 |
| Exemplar isolate | AY446894 |
Host evidence
- human: 5,520 GenBank records
- horse: 2 GenBank records (flagged for review)
Counts of nucleotide records annotated with that host. Evidence of provenance, not a statement of host range.
Where it occurs
Not searched yet. No country-level occurrence data has been curated for this virus. The WHO reported-case data on this site covers a limited set of diseases; a virus outside it gets no map rather than an empty one.
What it does
Not searched yet. Burden, severity and transmissibility figures have not been curated for this virus yet. When they are, each will carry the exact sentence from its source.
Vaccines
Nothing in use found in the sources searched. That is not the same as nothing existing; see the methods page for what was searched.
In development
| Name | Developer | Platform | Use | Stage | Jurisdictions | Trials | Source |
|---|---|---|---|---|---|---|---|
| mRNA-1647 | ModernaTX, Inc. | mrna | Routine immunisation | Phase 3 | Not searched yet | NCT05085366 NCT06133010 NCT05683457 | candidateId ctgov-mrna-1647-modernatx-inc (targetDisease 'CMV'); stage |
Antivirals
| Name | Mechanism | Use | Stage | Jurisdictions | Trials | Source |
|---|---|---|---|---|---|---|
| LetermovirPREVYMIS | Not searched yet | Treatment | Approved | US: approved | — | quote1 INDICATIONS AND USAGE PREVYMIS is a CMV DNA terminase complex inhibitor indicated for: Prophylaxis of cytomegalovirus (CMV) infection and disease in adult and pediatric patients 6 months of age and older and weighing at least 6 kg who are CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). Cytomegalovirus DNA Terminase Complex Inhibitor [EPC]; SPL id 282d792e-e2f2-4744-8526-4d18427c55cb · verified 2026-10-30 |
| MaribavirLivtencity | Not searched yet | Treatment | Approved | US: approved | — | quote1 INDICATIONS AND USAGE LIVTENCITY ® is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet [see Use in Specific Populations (8.4) and Clinical Studies (14) ] . Cytomegalovirus pUL97 Kinase Inhibitor [EPC]; SPL id 14acb19d-0258-47df-a01a-bdca1ea05e54 · verified 2026-10-30 |
| ValganciclovirVALGANCICLOVIR HYDROCHLORIDE | Non-nucleoside polymerase inhibitor | Treatment | Approved | US: approved | — | quote1 INDICATIONS AND USAGE N/A Valganciclovir hydrochloride is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: Adult Patients (1.1) • Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]; SPL id 48f8965d-d9ca-7c96-e063-6394a90af350 · verified 2026-10-30 |
Antibodies and immune globulins
Not searched yet. No US-approved antiviral antibody for this virus was found in the openFDA drug label endpoint.
Approval status is not a treatment recommendation. Dosing and eligibility are on the label and in national guidelines. This page does not give medical advice and does not render dosing. A development stage is not a measure of how well something works.
Related on this site
- Vaccine pipeline — candidates listed under “CMV”
- Other Orthoherpesviridae viruses
- Veterinary vaccines for this virus — animals, kept separate on purpose